FDA Labeling


Exablate Neuro is intended in the unilateral Thalamotomy (ventralis intermedius) treatment of Tremor-dominant Parkinson’s Disease with medication-refractory tremor.  Patients must be at least age 30.

Risks: Be sure to discuss with your physician all the risks involved with the focused ultrasound treatment.

Risks associated with thalamotomy include transient and/or permanent sensory paresthesias, numbness, imbalance, and/or gait disturbance. Risks and adverse events also associated with the Exablate Neuro treatment include sonication-related pain, sonication-related dizziness or nausea or potential for deep vein thrombosis associated with 3-4 hours on the treatment bed.

  • For short periods of time during the treatment you may experience dizziness, pain or other sensations.
  • There is the possibility that your tremor may return some months or years after treatment.
  • There is a small risk that you could develop temporary or permanent muscle weakness, imbalance, and/or gait disturbance, sensory effects (tingling, numbness) in your fingers or elsewhere in your body.
  • It is possible that your tremor may not improve.
  • This procedure does not treat the underlying disease nor prevent the progression of the disease.

Warning: Invalid argument supplied for foreach() in /home/customer/www/parkinsons-tremor.com/public_html/wp-content/plugins/wp-accessibility-helper-pro/inc/wah-front-functions.php on line 371